Connection

Charles Bennett to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Charles Bennett has written about Prostatic Neoplasms.
Charles Bennett
Connection Strength
8.283
Prostatic Neoplasms
  1. Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
    View in: PubMed
    Score: 0.367
  2. What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening? Clin Genitourin Cancer. 2017 12; 15(6):e977-e985.
    View in: PubMed
    Score: 0.360
  3. Population-Based Assessment of Determining Treatments for Prostate Cancer. JAMA Oncol. 2015 Apr; 1(1):67-8.
    View in: PubMed
    Score: 0.311
  4. Editorial comment. Urology. 2015 Feb; 85(2):413.
    View in: PubMed
    Score: 0.308
  5. Editorial comment. Urology. 2014 Nov; 84(5):1072.
    View in: PubMed
    Score: 0.302
  6. Editorial comment. Urology. 2015 Jan; 85(1):153-4.
    View in: PubMed
    Score: 0.302
  7. Editorial comment. Urology. 2014 Apr; 83(4):786-7.
    View in: PubMed
    Score: 0.290
  8. Editorial comment. Urology. 2014 Jan; 83(1):152-3; discussion 153.
    View in: PubMed
    Score: 0.283
  9. Editorial comment. Urology. 2013 Jul; 82(1):66.
    View in: PubMed
    Score: 0.274
  10. Editorial comment. Urology. 2013 Jan; 81(1):154; author reply 154.
    View in: PubMed
    Score: 0.266
  11. Editorial comment. Urology. 2012 Sep; 80(3):563.
    View in: PubMed
    Score: 0.258
  12. Editorial comment. Urology. 2012 Jul; 80(1):168.
    View in: PubMed
    Score: 0.255
  13. A 56-year-old physician who underwent a PSA test. Arch Intern Med. 2012 Feb 27; 172(4):311.
    View in: PubMed
    Score: 0.251
  14. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer". Arch Intern Med. 2010 Aug 09; 170(15):1397-9.
    View in: PubMed
    Score: 0.226
  15. Metastasis of genitourinary tumors to the head and neck region. Eur Arch Otorhinolaryngol. 2010 Feb; 267(2):273-9.
    View in: PubMed
    Score: 0.208
  16. Heeding our words: complexities of research among low-literacy populations. J Clin Oncol. 2009 Apr 20; 27(12):1938-40.
    View in: PubMed
    Score: 0.205
  17. Proxy assessment of health-related quality of life in african american and white respondents with prostate cancer: perspective matters. Med Care. 2009 Feb; 47(2):176-83.
    View in: PubMed
    Score: 0.203
  18. Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urology. 2006 Jul; 68(1):89-93.
    View in: PubMed
    Score: 0.170
  19. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol. 2005 Dec 01; 23(34):8894-905.
    View in: PubMed
    Score: 0.163
  20. Opportunities for disease state management in prostate cancer. Dis Manag. 2005 Aug; 8(4):235-44.
    View in: PubMed
    Score: 0.159
  21. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect. 2004 Jun; 7(2):115-25.
    View in: PubMed
    Score: 0.147
  22. Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004 Jun; 3(1):31-7.
    View in: PubMed
    Score: 0.147
  23. A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999-2015. Ann Epidemiol. 2021 07; 59:24-32.
    View in: PubMed
    Score: 0.118
  24. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001 Apr; 57(4):727-32.
    View in: PubMed
    Score: 0.118
  25. Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity. Urology. 2001 Feb; 57(2):275-80.
    View in: PubMed
    Score: 0.117
  26. Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer: Results from a national survey. Eur J Cancer Care (Engl). 2021 Jan; 30(1):e13301.
    View in: PubMed
    Score: 0.115
  27. Patient- and area-level predictors of prostate cancer among South Carolina veterans: a spatial analysis. Cancer Causes Control. 2020 Mar; 31(3):209-220.
    View in: PubMed
    Score: 0.109
  28. Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Qual Life Res. 1999 Aug; 8(5):461-70.
    View in: PubMed
    Score: 0.105
  29. A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res. 1999 May; 8(3):171-80.
    View in: PubMed
    Score: 0.103
  30. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct; 37(10):2099-2108.
    View in: PubMed
    Score: 0.101
  31. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures. J Urol. 1998 Nov; 160(5):1765-9.
    View in: PubMed
    Score: 0.100
  32. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998 Sep; 16(9):3101-4.
    View in: PubMed
    Score: 0.099
  33. Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998 Jul-Sep; 18(3):278-86.
    View in: PubMed
    Score: 0.097
  34. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2018 08; 16(4):313-317.
    View in: PubMed
    Score: 0.097
  35. Variations in the use of prostate cancer staging tests: results from one NCCN Institution. Oncology (Williston Park). 1997 Nov; 11(11A):155-7.
    View in: PubMed
    Score: 0.093
  36. Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. Urology. 1997 Feb; 49(2):218-24.
    View in: PubMed
    Score: 0.088
  37. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol. 1997; 32 Suppl 3:86-8.
    View in: PubMed
    Score: 0.088
  38. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
    View in: PubMed
    Score: 0.084
  39. Performance measurement in prostate cancer care: beyond report cards. Urology. 1996 Mar; 47(3):356-65.
    View in: PubMed
    Score: 0.083
  40. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5.
    View in: PubMed
    Score: 0.078
  41. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology. 1995 Apr; 45(4):633-40.
    View in: PubMed
    Score: 0.078
  42. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42.
    View in: PubMed
    Score: 0.076
  43. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep; 112(5):548-60.
    View in: PubMed
    Score: 0.069
  44. Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J Clin Pharmacol. 2013 Jul; 53(7):773-8.
    View in: PubMed
    Score: 0.068
  45. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31.
    View in: PubMed
    Score: 0.068
  46. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4.
    View in: PubMed
    Score: 0.067
  47. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5.
    View in: PubMed
    Score: 0.062
  48. Patterns of care related to age of men with prostate cancer. Cancer. 1991 May 15; 67(10):2633-41.
    View in: PubMed
    Score: 0.059
  49. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar; 75(3):623-9.
    View in: PubMed
    Score: 0.052
  50. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
    View in: PubMed
    Score: 0.045
  51. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer. 2005 Jun; 4(1):15-23.
    View in: PubMed
    Score: 0.039
  52. Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther. 2004 Dec; 3(12):1298-303.
    View in: PubMed
    Score: 0.038
  53. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14):2927-41.
    View in: PubMed
    Score: 0.037
  54. Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology. 2003 Jan; 61(1):172-8.
    View in: PubMed
    Score: 0.033
  55. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer. 2002 Sep; 1(2):105-14.
    View in: PubMed
    Score: 0.033
  56. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002 Jul 15; 95(2):361-76.
    View in: PubMed
    Score: 0.032
  57. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 04; 132(7):566-77.
    View in: PubMed
    Score: 0.028
  58. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000; (2):CD001526.
    View in: PubMed
    Score: 0.027
  59. Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000; 4(3):259-63;discussion 265.
    View in: PubMed
    Score: 0.027
  60. QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Williston Park). 1999 Jun; 13(6):823-32; discussion 835-8.
    View in: PubMed
    Score: 0.026
  61. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.
    View in: PubMed
    Score: 0.026
  62. Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997 Sep; 50(3):366-72.
    View in: PubMed
    Score: 0.023
  63. Approaches to prostate cancer by managed care organizations. Urology. 1997 Jul; 50(1):79-86.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.